प्रोपाफेनोन और सोटालोल का इंटरैक्शन

• The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) or other antiarrhythmic drugs is uncertain, but at present, it is prudent to consider any IC antiarrhythmic to have a significant proarrhythmic risk in patients with structural heart disease.

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval.

It may also worsen premature ventricular contractions or supraventricular arrhythmias, and it may prolong the QT interval.

Use with Drugs that Prolong the QT Interval and Antiarrhythmic Agents The use of propafenone hydrochloride extended-release capsules in conjunction with other drugs that prolong the QT interval has not been extensively studied.

In clinical trials using propafenone immediate-release tablets, patients who were receiving beta-blockers concurrently did not experience an increased incidence of side effects.

Antiarrhythmic and other QT Prolonging Drugs Withdraw other Class I or Class III antiarrhythmic agents prior to dosing with sotalol.